321 related articles for article (PubMed ID: 24376144)
21. Quality by design approach for viral clearance by protein a chromatography.
Zhang M; Miesegaes GR; Lee M; Coleman D; Yang B; Trexler-Schmidt M; Norling L; Lester P; Brorson KA; Chen Q
Biotechnol Bioeng; 2014 Jan; 111(1):95-103. PubMed ID: 23860745
[TBL] [Abstract][Full Text] [Related]
22. Host cell protein removal from biopharmaceutical preparations: Towards the implementation of quality by design.
Goey CH; Alhuthali S; Kontoravdi C
Biotechnol Adv; 2018; 36(4):1223-1237. PubMed ID: 29654903
[TBL] [Abstract][Full Text] [Related]
23. Integrated continuous production of recombinant therapeutic proteins.
Warikoo V; Godawat R; Brower K; Jain S; Cummings D; Simons E; Johnson T; Walther J; Yu M; Wright B; McLarty J; Karey KP; Hwang C; Zhou W; Riske F; Konstantinov K
Biotechnol Bioeng; 2012 Dec; 109(12):3018-29. PubMed ID: 22729761
[TBL] [Abstract][Full Text] [Related]
24. Caprylic acid-induced impurity precipitation from protein A capture column elution pool to enable a two-chromatography-step process for monoclonal antibody purification.
Zheng J; Wang L; Twarowska B; Laino S; Sparks C; Smith T; Russell R; Wang M
Biotechnol Prog; 2015; 31(6):1515-25. PubMed ID: 26280674
[TBL] [Abstract][Full Text] [Related]
25. Protein aggregation kinetics during Protein A chromatography. Case study for an Fc fusion protein.
Shukla AA; Gupta P; Han X
J Chromatogr A; 2007 Nov; 1171(1-2):22-8. PubMed ID: 17920607
[TBL] [Abstract][Full Text] [Related]
26. High-throughput mAb expression and purification platform based on transient CHO.
Barnard GC; Hougland MD; Rajendra Y
Biotechnol Prog; 2015; 31(1):239-47. PubMed ID: 25403790
[TBL] [Abstract][Full Text] [Related]
27. Real-time monitoring and control of the load phase of a protein A capture step.
Rüdt M; Brestrich N; Rolinger L; Hubbuch J
Biotechnol Bioeng; 2017 Feb; 114(2):368-373. PubMed ID: 27543789
[TBL] [Abstract][Full Text] [Related]
28. The dynamics of the CHO host cell protein profile during clarification and protein A capture in a platform antibody purification process.
Hogwood CE; Tait AS; Koloteva-Levine N; Bracewell DG; Smales CM
Biotechnol Bioeng; 2013 Jan; 110(1):240-51. PubMed ID: 22806637
[TBL] [Abstract][Full Text] [Related]
29. Evaluation and comparison of alternatives to Protein A chromatography Mimetic and hydrophobic charge induction chromatographic stationary phases.
Ghose S; Hubbard B; Cramer SM
J Chromatogr A; 2006 Jul; 1122(1-2):144-52. PubMed ID: 16750212
[TBL] [Abstract][Full Text] [Related]
30. Effect of the conserved oligosaccharides of recombinant monoclonal antibodies on the separation by protein A and protein G chromatography.
Gaza-Bulseco G; Hickman K; Sinicropi-Yao S; Hurkmans K; Chumsae C; Liu H
J Chromatogr A; 2009 Mar; 1216(12):2382-7. PubMed ID: 19181325
[TBL] [Abstract][Full Text] [Related]
31. Improved process analytical technology for protein a chromatography using predictive principal component analysis tools.
Hou Y; Jiang C; Shukla AA; Cramer SM
Biotechnol Bioeng; 2011 Jan; 108(1):59-68. PubMed ID: 20672251
[TBL] [Abstract][Full Text] [Related]
32. Studying host cell protein interactions with monoclonal antibodies using high throughput protein A chromatography.
Sisodiya VN; Lequieu J; Rodriguez M; McDonald P; Lazzareschi KP
Biotechnol J; 2012 Oct; 7(10):1233-41. PubMed ID: 22623327
[TBL] [Abstract][Full Text] [Related]
33. An empirical modeling platform to evaluate the relative control discrete CHO cell synthetic processes exert over recombinant monoclonal antibody production process titer.
McLeod J; O'Callaghan PM; Pybus LP; Wilkinson SJ; Root T; Racher AJ; James DC
Biotechnol Bioeng; 2011 Sep; 108(9):2193-204. PubMed ID: 21445882
[TBL] [Abstract][Full Text] [Related]
34. Expanded bed protein A affinity chromatography of a recombinant humanized monoclonal antibody: process development, operation, and comparison with a packed bed method.
Fahrner RL; Blank GS; Zapata GA
J Biotechnol; 1999 Oct; 75(2-3):273-80. PubMed ID: 10553663
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibody purification using activated carbon as a replacement for Protein A affinity chromatography.
Ishihara T; Miyahara M; Yamamoto K
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Dec; 1102-1103():1-7. PubMed ID: 30366207
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of using continuous chromatography in downstream processing: Comparison of costs and product quality for a hybrid process vs. a conventional batch process.
Ötes O; Flato H; Winderl J; Hubbuch J; Capito F
J Biotechnol; 2017 Oct; 259():213-220. PubMed ID: 28684321
[TBL] [Abstract][Full Text] [Related]
37. Weak partitioning chromatography for anion exchange purification of monoclonal antibodies.
Kelley BD; Tobler SA; Brown P; Coffman JL; Godavarti R; Iskra T; Switzer M; Vunnum S
Biotechnol Bioeng; 2008 Oct; 101(3):553-66. PubMed ID: 18727127
[TBL] [Abstract][Full Text] [Related]
38. The distinctive separation attributes of mixed-mode resins and their application in monoclonal antibody downstream purification process.
Chen J; Tetrault J; Zhang Y; Wasserman A; Conley G; Dileo M; Haimes E; Nixon AE; Ley A
J Chromatogr A; 2010 Jan; 1217(2):216-24. PubMed ID: 19819462
[TBL] [Abstract][Full Text] [Related]
39. Antibody capture by mixed-mode chromatography: a comprehensive study from determination of optimal purification conditions to identification of contaminating host cell proteins.
Pezzini J; Joucla G; Gantier R; Toueille M; Lomenech AM; Le Sénéchal C; Garbay B; Santarelli X; Cabanne C
J Chromatogr A; 2011 Nov; 1218(45):8197-208. PubMed ID: 21982448
[TBL] [Abstract][Full Text] [Related]
40. Single pass tangential flow filtration to debottleneck downstream processing for therapeutic antibody production.
Dizon-Maspat J; Bourret J; D'Agostini A; Li F
Biotechnol Bioeng; 2012 Apr; 109(4):962-70. PubMed ID: 22094920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
